Parabilis Medicines is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Parabilis's stapled helical peptides (helicons) maintain structure to penetrate cell membranes and bind flat intracellular protein surfaces, addressing the 80% of disease-driving proteins with no small-molecule pockets, potentially creating a platform that can remediate any protein network error inside the cell.